Mizuho increases its price target for DexCom (DXCM), whilst maintaining an Outperform rating. This biotech company continues to demonstrate a compelling Return on Equity (ROE) with a robust 24%. There is ease concerning the company's ability to manage its debt alongside consistent growth. However, DexCom's share price appears to be lagging behind that of its medical peers in the current year. DexCom is committed to rectifying earlier missteps and has successfully had its stock upgraded to a Strong Buy. The firm's high P/E ratio is balanced by stellar growth figures in the Continuous Glucose Monitoring (CGM) Revolution. The biotech firm's stock is significantly outperforming its medical peers this year, thanks to strong momentum and continual earnings that exceed expectations. DexCom has robustly responded to new challenges, with ratings being upgraded as a result. Recent exciting developments include a strategic partnership with ΕURA, a scheduled earnings release, and FDA approval of a new diabetes device. Further, despite potential risks and margin challenges, the stock enjoys a high recommendation from investment giants Goldman Sachs and Barclays. Finally, the company is planning a US launch of the FDA approved wearable glucose management system.
Dexcom DXCM News Analytics from Thu, 24 Oct 2024 07:00:00 GMT to Sat, 26 Jul 2025 03:54:27 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -2
